Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, Remo Panaccione et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flávio Steinwurz et al.|Gastroenterology|2025Cited by 46
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Silvio Danese, Tadakazu Hisamatsu et al.|The Lancet|2025Cited by 44
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel DiseaseBruce E. Sands, Chenglong Han, Julián Panés et al.|Value in Health|2024Cited by 10